Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin.
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Both EGF and insulin, or IGF, stimulate the growth of many cell types by activating receptors that contain tyrosine kinase activities. A monoclonal antibody (mAb 225) against the EGF receptor produced in this laboratory has been shown to competitively inhibit EGF binding and block activation of receptor tyrosine kinase. Here we report that a human colorectal carcinoma cell line, DiFi, which expresses high levels of EGF receptors on plasma membranes, can be induced to undergo G1 cell cycle arrest and programmed cell death (apoptosis) when cultured with mAb 225 at concentrations that saturate EGF receptors. Addition of IGF-1 or high concentrations of insulin can delay apoptosis induced by mAb 225, while the G1 arrest cannot be reversed by either IGF-1 or insulin. Insulin/IGF-1 cannot activate EGF receptor tyrosine kinase that has been inhibited by mAb 225. Moreover, an mAb against the IGF-1 receptor, which has little direct effect on DiFi cell growth, can block the capacity of insulin/IGF-1 to delay apoptosis induced by mAb 225, suggesting that the insulin/IGF-1-mediated delay of apoptosis is acting through the IGF-1 receptor. In contrast, insulin/IGF-1 cannot delay the apoptosis caused by the DNA damaging agent, cisplatin. The results indicate that EGF receptor activation is required both for cell cycle progression and for prevention of apoptosis in DiFi cells, and that a signal transduction pathway shared by receptors for insulin/IGF-1 and EGF may be involved in regulating apoptosis triggered by blockade of the EGF receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics
Kerr, J. F. R., Wyllie, A. H., & Currie, A. R. (1972) · British Journal of Cancer · doi:10.1038/bjc.1972.33 · Cited by 15,725
Cell Death: The Significance of Apoptosis
Wyllie, A. H., Kerr, J. F. R., & Currie, A. R. (1980) · International Review of Cytology · doi:10.1016/s0074-7696(08)62312-8 · Cited by 7,162
Rinderknecht, E., & Humbel, R. E. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40889-1 · Cited by 1,545
RECEPTORS FOR EPIDERMAL GROWTH FACTOR AND OTHER POLYPEPTIDE MITOGENS
Carpenter, G. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004313 · Cited by 1,281
Insulin Stimulates the Phosphorylation of the 95,000-Dalton Subunit of Its Own Receptor
Kasuga, M., Karlsson, F. A., & Kahn, C. R. (1982) · Science · doi:10.1126/science.7031900 · Cited by 1,126
DeCaprio, J. A., Ludlow, J. W., Lynch, D., Furukawa, Y., Griffin, J., Piwnica-Worms, H., Huang, C.-M., & Livingston, D. M. (1989) · Cell · doi:10.1016/0092-8674(89)90507-2 · Cited by 897
Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., & Mendelsohn, J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.5.1337 · Cited by 791
Self-citationActivation of Programmed Cell Death in the Rat Ventral Prostate after Castration*
KYPRIANOU, N., & ISAACS, J. T. (1988) · Endocrinology · doi:10.1210/endo-122-2-552 · Cited by 720
Neal, D., Bennett, M., Hall, R., Marsh, C., Abel, P., Sainsbury, J. R. C., & Harris, A. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91386-8 · Cited by 604
Ludlow, J. W., DeCaprio, J. A., Huang, C.-M., Lee, W.-H., Paucha, E., & Livingston, D. M. (1989) · Cell · doi:10.1016/0092-8674(89)90983-5 · Cited by 494
Cited by
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Review of epidermal growth factor receptor biology
Herbst, R. S. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.11.041 · Cited by 1,390
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Self-citationStatus of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J., & Baselga, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,255
Self-citationBindingDB (2025) · PubMed · doi:10.7270/q2dr317m · Cited by 843
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829
The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy
Woodburn, J. R. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00045-x · Cited by 827
Epidermal Growth Factor Receptor Targeting in Cancer
MENDELSOHN, J., & BASELGA, J. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 693
Self-citationAmplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657
Párrizas, M., Saltiel, A. R., & LeRoith, D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.1.154 · Cited by 653
ErbB Receptors: Directing Key Signaling Networks Throughout Life
Holbro, T., & Hynes, N. E. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121440 · Cited by 640
Sabbah, D. A., Hajjo, R., & Sweidan, K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200303123102 · Cited by 591
The EGFR as a target for anticancer therapy—focus on cetuximab
Baselga, J. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00233-7 · Cited by 563
Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy
Baselga, J. (2002) · The Oncologist · doi:10.1634/theoncologist.7-2004-2 · Cited by 510
Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity
Weihua, Z., Tsan, R., Huang, W.-C., Wu, Q., Chiu, C.-H., Fidler, I. J., & Hung, M.-C. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.03.015 · Cited by 490
Xiong, H. Q., Rosenberg, A., LoBuglio, A., Schmidt, W., Wolff, R. A., Deutsch, J., Needle, M., & Abbruzzese, J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.040 · Cited by 479
Herbst, R. S., & Shin, D. M. (2002) · Cancer · doi:10.1002/cncr.10372 · Cited by 446
EGFR Signaling and Drug Discovery
Lurje, G., & Lenz, H.-J. (2009) · Oncology · doi:10.1159/000279388 · Cited by 442
Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy
Raymond, E., Faivre, S., & Armand, J. P. (2000) · Drugs · doi:10.2165/00003495-200060001-00002 · Cited by 398
A meta‐analysis of the association of physical activity with reduced risk of colorectal cancer
Samad, A. K. A., Taylor, R. S., Marshall, T., & Chapman, M. A. S. (2005) · Colorectal Disease · doi:10.1111/j.1463-1318.2005.00747.x · Cited by 347
Tabernero, J., Van Cutsem, E., Díaz-Rubio, E., Cervantes, A., Humblet, Y., André, T., Van Laethem, J.-L., Soulié, P., Casado, E., Verslype, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.2183 · Cited by 337
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
Normanno, N., Bianco, C., De Luca, A., Maiello, M. R., & Salomon, D. S. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100001 · Cited by 336
The epidermal growth factor receptor as a target for cancer therapy.
Mendelsohn, J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080003 · Cited by 330
Self-citationThe metabolic syndrome and risk of incident colorectal cancer
Ahmed, R. L., Schmitz, K. H., Anderson, K. E., Rosamond, W. D., & Folsom, A. R. (2006) · Cancer · doi:10.1002/cncr.21950 · Cited by 325
Obesity and cancer: Symposium on ‘Diet and cancer’
Pischon, T., Nöthlings, U., & Boeing, H. (2008) · Proceedings of the Nutrition Society · doi:10.1017/s0029665108006976 · Cited by 320
The epidermal growth factor receptor–tyrosine kinase: A promising therapeutic target in solid tumors
Ritter, C. A., & Arteaga, C. L. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50027 · Cited by 311
Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes
Gunter, M. J., & Leitzmann, M. F. (2006) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2005.06.011 · Cited by 310
ARTEAGA, C. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70085-7 · Cited by 302
Matar, P., Rojo, F., Cassia, R., Moreno-Bueno, G., Di Cosimo, S., Tabernero, J., Guzmán, M., Rodriguez, S., Arribas, J., Palacios, J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0870 · Cited by 277
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Brand, T. M., Iida, M., & Wheeler, D. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15050 · Cited by 273
Normanno, N., Campiglio, M., De Luca, A., Somenzi, G., Maiello, M., Ciardiello, F., Gianni, L., Salomon, D. S., & Menard, S. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf020 · Cited by 273
Epidermal growth factor receptor tyrosine kinase
Ward, W. H. J., Cook, P. N., Slater, A. M., Davies, D. H., Holdgate, G. A., & Green, L. R. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90042-6 · Cited by 261
Colon Cancer: A Civilization Disorder
Watson, A. J. M., & Collins, P. D. (2011) · Digestive Diseases · doi:10.1159/000323926 · Cited by 257
Huang, S.-M., & Harari, P. M. (1999) · Investigational New Drugs · doi:10.1023/a:1006384521198 · Cited by 253
Epidermal growth factor receptor: a promising target in solid tumours
Laskin, J. J., & Sandler, A. B. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.10.002 · Cited by 253
Biology of Interactions: Antiepidermal Growth Factor Receptor Agents
Harari, P. M., Allen, G. W., & Bonner, J. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8984 · Cited by 214
Li, X., & Fan, Z. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0157 · Cited by 179
Self-citationRowinsky, E. K. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104433 · Cited by 178
Lu, Y., Li, X., Liang, K., Luwor, R., Siddik, Z. H., Mills, G. B., Mendelsohn, J., & Fan, Z. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0589 · Cited by 170
Self-citationIL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells
McMichael, E. L., Jaime-Ramirez, A. C., Guenterberg, K. D., Luedke, E., Atwal, L. S., Campbell, A. R., Hu, Z., Tatum, A. S., Kondadasula, S. V., Mo, X., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0004 · Cited by 70
“Cetuximabmediated inhibition of EGFR-mediated signal transduction in tumor cells leads to G1 arrest and the induction of apoptosis in vitro (5, 6) and in murine xenograft models (7, 8).”
Skvortsov, S., Sarg, B., Loeffler-Ragg, J., Skvortsova, I., Lindner, H., Werner Ott, H., Lukas, P., Illmensee, K., & Zwierzina, H. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1551.3.12 · Cited by 33
Metadata
- Authors
- Wu, X., Fan, Z., Masui, H., Rosen, N., & Mendelsohn, J.
- Venue
- Journal of Clinical Investigation
- Published
- 1995-04-01
- Volume
- 95
- Issue
- 4
- Pages
- 1897-1905
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2038882649
- Cited by
- 381
- References
- 38
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.